Is There a Real Replacement for Wegovy — or Just a Different Path?

The myth: any GLP-1 medicine can simply swap in for another

The idea that GLP-1 weight-loss medicines are interchangeable gets repeated a lot online, and it is worth addressing directly because it shapes how people approach switching. Wegovy and Mounjaro both slow gastric emptying, reduce appetite and support weight loss alongside a reduced-calorie diet. The surface similarities are real. But the mechanism, the titration schedule and the side-effect profile differ enough that moving from one to the other requires a proper clinical review rather than a like-for-like substitution.

Semaglutide activates a single receptor pathway, GLP-1. Tirzepatide activates two: GLP-1 and GIP. That dual action is the reason tirzepatide tends to produce steeper average reductions in trials. In SURMOUNT-5, published in the New England Journal of Medicine in 2025, tirzepatide achieved greater average weight loss than semaglutide 2.4mg in a direct head-to-head study over 72 weeks in adults with obesity. But average figures from trials tell you about populations, not individuals. Your response depends on your biology, your adherence, your diet, any medications you take alongside treatment and a handful of other factors a prescriber is trained to weigh up.

Before assuming you need a replacement at all, it is worth asking whether the issue with Wegovy was dose, duration, side effects or something else. Those answers change the recommendation considerably, and injection technique and site rotation can sometimes affect how well the medicine is absorbed too.

When Wegovy itself might not be finished yet

If you have been on Wegovy and feel the results have slowed or stopped, the first conversation is not automatically about switching. The MHRA approved a new 7.2mg maintenance dose for Wegovy in January 2026, and the dedicated single-dose 7.2mg pen received approval on 14 April 2026. Early trial data at that higher dose reported around 20.7% average weight loss over 72 weeks, approaching the figures seen with tirzepatide's highest dose. For some people, escalating within semaglutide rather than switching medicines is clinically appropriate.

Similarly, if side effects were the main problem with Wegovy, a slower titration or a short pause in dose escalation sometimes resolves things. The gastrointestinal effects that most commonly prompt people to stop (nausea, loose stools, discomfort after eating) tend to be most pronounced in the first few weeks after a dose increase and settle for most people with time. That is not a reason to push through something genuinely distressing, but it is a reason to talk to a prescriber before assuming the medicine has failed you.

You can read more about how Wegovy performs against placebo in trial data if you want a clearer baseline for what the medicine is expected to deliver before making any decisions about switching. Understanding what "working" looks like is a reasonable starting point.

What Mounjaro offers as a clinical alternative, and who it suits

For people who have genuinely not responded to semaglutide, or who cannot tolerate it, tirzepatide is the most established clinical alternative licensed for weight management in the UK. The full picture on Wegovy and the evidence behind it is worth reading alongside the Mounjaro data if you are trying to compare both options honestly.

Mounjaro is licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Treatment starts at 2.5mg (a dose designed to let your system adjust gradually) and is titrated by a prescriber in four-week steps up to 15mg. The titration schedule differs from Wegovy's, which is another reason switching is not as simple as swapping one pen for another.

The side-effect profile is broadly similar: nausea, changes in bowel habit and indigestion are the most commonly reported effects with tirzepatide, as documented on the NHS tirzepatide medicines page. People switching from semaglutide sometimes find those effects feel familiar; others notice they respond differently. If you are currently on oral contraceptives, there is one important practical note: MHRA guidance advises adding a non-oral method of contraception for the first four weeks of tirzepatide and for four weeks after each dose increase, because absorption of the pill may be reduced. That applies to tirzepatide specifically and does not have an equivalent evidence base for semaglutide.

For context on how the two medicines compare against each other more directly, the semaglutide comparison pages cover the shared mechanism between Wegovy and Ozempic, which clarifies why the latter is not a weight-loss replacement even though it contains the same active ingredient.

How to switch medicines safely, and what to expect from the process

If a prescriber agrees that moving from Wegovy to Mounjaro (or vice versa) is clinically appropriate for you, the transition is usually straightforward in practical terms but needs to be managed. There is no standard universal washout period required between the two, but the starting dose and titration speed will be set according to your current dose, how long you have been on treatment and your clinical history. A prescriber will also want to know whether you have any evidence of your current dose and weight, transfer patients at nume are asked to provide that before a new prescription is issued.

If cost has been part of the calculation, it is useful to understand that both medicines carry a private prescription cost that includes consultation and aftercare with a regulated service. The price context across weight-loss treatments is explained on our Wegovy payment options page, and the broader treatment overview at weight loss treatments covers both pillars side by side.

One practical note: if you are planning a switch around a particular point in the month (payday, a Monday order to align with your week, or before a holiday) it helps to build in time for the consultation. Same-day clinical review is available at nume Monday to Friday, but a prescriber still needs to assess you before anything is sent. Plan a few days' buffer where you can.

The NICE appraisal of tirzepatide (TA1026) and the guidance on choosing where to get Wegovy are both worth reading if you want to understand the regulatory and clinical landscape before your consultation. Our prescribers at our clinical team page can tell you more about how switching decisions are made in practice.